Akari Therapeutics
AKTX
11 hedge funds and large institutions have $1.84M invested in Akari Therapeutics in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
27% less funds holding
Funds holding: 15 → 11 (-4)
56% less capital invested
Capital invested by funds: $4.19M → $1.84M (-$2.35M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.68M |
| 2 |
Renaissance Technologies
New York
|
+$89.8K |
| 3 |
Millennium Management
New York
|
+$81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.63M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.57K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$6.31K |
| 4 |
VF
Virtu Financial
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.44M | +$1.68M | +5,342 | +117% |
|
|
OFW
2
Omnia Family Wealth
Aventura,
Florida
| $142K | – | – | – |
|
|
NMC
3
NEA Management Company
Timonium,
Maryland
| $82.2K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $52K | +$89.8K | +285 | +413% |
|
|
5
Millennium Management
New York
| $47K | +$81K | +257 | +372% |
|
6
LPL Financial
San Diego,
California
| $24.4K | – | – | – |
|
|
HP
7
Hikari Power
Tokyo,
Japan
| $24K | – | – | – |
|
|
BMCM
8
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
| $18.2K | – | – | – |
|
9
Geode Capital Management
Boston,
Massachusetts
| $5.5K | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $543 | – | – | – |
|
|
TC
11
Truvestments Capital
Sarasota,
Florida
| $183 | – | – | – |
|
|
AC
12
Armistice Capital
New York
| – | -$1.63M | -4,338 | Closed |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$7.57K | -19 | Closed |
|
|
TSS
14
Two Sigma Securities
New York
| – | -$6.31K | -17 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$5K | -13 | Closed |
|
AKTX Hedge Fund Activity: Q1 2023 in Review
11 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2023, worth a combined $1.84M — down 56% from $4.19M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AKTX and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $1.68M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.63M sold.
- 11 institutional investors held Akari Therapeutics (AKTX) as of Q1 2023, down from 15 in Q4 2022.
- Funds reported $1.84M of Akari Therapeutics stock for Q1 2023, down 56% quarter-over-quarter.
- 0 funds opened new Akari Therapeutics positions in Q1 2023 and 4 closed out, a net change of -4 holders.
- The largest Akari Therapeutics buyer in Q1 2023 was Sabby Management, an estimated $1.68M added.
- The largest Akari Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2023.